Outcomes of Renal Replacement in Mexico
Chronic Kidney Disease - Stage V · Chronic Kidney Disease on Hemodialysis
What this study involves
The registry does not currently label this study as recruiting. Ask about its status before planning a screening visit.
- Study type
- Observational
- Phase
- Not applicable / not listed
- Age range
- Not specified - Not specified
- Sex eligible
- All sexes
- Healthy volunteers
- Not accepted
- Participants
- 290 Estimated
These are starting points, not an eligibility decision. The research team must review the full requirements.
About the research
A descriptive, observational, prospective, multicenter study aimed at describing the main clinical outcomes of patients with chronic kidney disease receiving any form of renal replacement therapy in Mexico.
Who may be able to participate?
The list below is the sponsor’s full registry wording. It can include conditions, prior treatment, test results and other requirements. A match in search does not mean you qualify.
Inclusion Criteria:
- Willingness to participate and provision of written informed consent
- Diagnosis of chronic kidney disease and treatment with hemodialysis or peritoneal dialysis for ≥3 months
- Availability of a medical record containing information on the study variables
- Receiving care at one of the participating centers
Exclusion Criteria:
- Life expectancy \<3 months due to a cause unrelated to chronic kidney disease
Study population
Patients with chronic kidney disease undergoing hemodialysis or peritoneal dialysis in the units participating in the project
Understand screeningTreatment, groups and participation
The registry may describe treatments and study duration without a complete visit calendar. Ask the study team for the exact schedule, procedures, risks, costs and alternatives. Keep your usual care plan unless your treating clinician tells you otherwise.
- Assignment
- Not reported
- Masking
- Not reported
CKD on RRT
Patients with chronic kidney disease undergoing renal replacement therapy (RRT) in Mexico
What researchers are measuring
Outcome measures describe what is being studied. They are not proof that a treatment works.
Primary measures
All-cause mortality
Time frame: From enrollment in the study until death from any cause or end of follow-up, assessed up to 3 years.
The occurrence of death from any cause during the follow-up period, as documented in the patient's medical record
Secondary measures
Hospitalizations per patient-year
Time frame: From enrollment until the end of follow-up, assessed up to 3 years
The number of hospitalizations recorded during the study follow-up, expressed per patient-year
Infection rate
Time frame: From enrollment until the end of follow-up, assessed up to 3 years
The number of documented infection episodes during the follow-up period, as recorded in the medical records, expressed per patient-year.
Review the complete result tables and limitations in the official record.
Open official results ↗Research locations (0)
The overall study status and a local site’s status can differ. Confirm that location’s availability before traveling.
No locations are listed. Use the official study contact.
Study team and timeline
- Lead sponsor
- Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
- Study start
- 2027-01 Estimated
- Primary completion
- 2029-12 Estimated
- Study completion
- 2029-12 Estimated
- First posted
- Mar 16, 2026 Actual
- Last updated
- Nov 10, 2026 Actual
Official study contacts
Official study title
Clinical Outcomes Study of Mexican Patients With Chronic Kidney Disease on Renal Replacement Therapy
Ask Wellness Clinical Research
Your message goes to WCR, including when this study is run by another organization. WCR may offer general guidance but may not operate this trial, have access to its team or be able to enroll you.
Source: ClinicalTrials.gov API v2. Information is submitted by sponsors and investigators. NLM does not approve the safety or science of all listed studies. Registry disclaimer.
Retrieved: Nov 12, 2026 · Last registry update: Nov 10, 2026